Background: Early and correct diagnosis of acute myocardial infarction (AMI) is of utmost importance to enable the immediate and intensified treatment which consequently reduces the mortality due to AMI. Under this condition, cardiac markers are used to evaluate heart functions. Glycogen phosphorylase BB (GPBB) is new marker invented to diagnose AMI within 4 h of onset of chest pain.
Objective: The objective of the study is to compare the sensitivity and specificity of GPBB with myoglobin (MB) and creatine kinase MB (CKMB) within 4 h after the onset of chest pain.
Materials and Methods: This study includes 150 AMI patients and 100 normal healthy individuals as controls. In all the cases and controls, serum GPBB and MB were measured by enzyme-linked immunosorbent assay, whereas CK-MB was measured by diagnostic kit supplied by ERBA.
Results: The sensitivity and specificity of GPBB were greater than MB and CKMB within 4 h after the onset of chest pain.
Conclusion: GPBB was the most sensitive and specific cardiac marker compared to MB and CKMB in AMI patients during the first 4 h after the onset of chest pain. Hence, GPBB can be used for the early diagnosis of AMI.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
